Summary & Overview
HCPCS Level II J2796: Romiplostim Injection, 10 micrograms
HCPCS Level II code J2796 denotes a 10 microgram dose of romiplostim administered by injection. Romiplostim is a thrombopoietin receptor agonist used to raise platelet counts in patients with certain causes of thrombocytopenia; accurate coding for dose-based biologic products is critical for billing, utilization tracking, and patient access. Nationally, biologic drug codes like J2796 matter because they drive specialty drug spend lines, influence site-of-care decisions, and affect prior authorization and coverage policies across commercial and public payers.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the code’s clinical context, common billing considerations, and the types of benchmarks and policy items typically examined alongside such HCPCS Level II drug codes. The content outlines what to expect in payer coverage approaches, common modifier usage for service reporting, and the operational implications for infusion suites and physician offices.
This summary prepares clinicians, billing teams, and policy analysts to interpret payer documentation, align charge and administration practices with the code’s dose unit, and identify where to look for payer-specific guidance and reimbursement rules.
Billing Code Overview
HCPCS Level II code J2796 represents an injection of romiplostim, 10 micrograms. This code identifies the administration unit for the thrombopoietin receptor agonist romiplostim used to increase platelet counts in patients with thrombocytopenia.
Service type: Parenteral drug administration (injectable biologic)
Typical site of service: Outpatient infusion/clinic setting or physician office where injectable biologic therapies are administered
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with chronic immune thrombocytopenia (ITP) experiencing persistent thrombocytopenia and bleeding risk despite first-line therapies. The patient presents to an outpatient hematology clinic for administration of romiplostim. Prior to injection, the clinician reviews recent platelet counts, concurrent medications, and prior responses to thrombopoietic agents. Consent and counseling about efficacy and potential adverse events (thromboembolic risk, bone marrow fibrosis) are documented. The medication J2796 (romiplostim, 10 micrograms) is prepared by pharmacy or clinic nursing under sterile technique. The injection is administered subcutaneously, typically in the abdomen or thigh, by a registered nurse or qualified provider. Post-injection observation for a brief period is performed to monitor for immediate reactions. Serial platelet monitoring is scheduled, and dosing adjustments are made based on platelet response. Billing uses HCPCS Level II code J2796 with appropriate service modifiers and encounter documentation reflecting site of service (outpatient clinic or physician office) and any procedural circumstances.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
11 | Professional component | Use when reporting the professional component of a split service if applicable to associated professional services rather than the drug itself. |